InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPRGet Rating) in a report released on Monday. The firm set a “sell” rating on the stock.

InspireMD stock opened at $2.18 on Monday. The business’s 50-day simple moving average is $2.58. InspireMD has a 52 week low of $1.91 and a 52 week high of $6.82. The stock has a market capitalization of $18.14 million, a PE ratio of -1.04 and a beta of 1.39.

InspireMD (NYSE:NSPRGet Rating) last posted its quarterly earnings data on Tuesday, March 8th. The company reported ($0.53) earnings per share (EPS) for the quarter. InspireMD had a negative return on equity of 45.79% and a negative net margin of 345.80%. The firm had revenue of $1.38 million during the quarter.

InspireMD Company Profile (Get Rating)

InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery.

Featured Articles

Want More Great Investing Ideas?

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.